This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
=== Normal === In healthy adults, the normal concentrations of CRP varies between 0.8 mg/L and 3.0 mg/L. However, some healthy adults show elevated CRP at 10 mg/L. CRP concentrations also increase with age, possibly due to subclinical conditions. Additionally, there are seasonal variations of CRP concentrations, with highest levels occurring in the winter. Gene polymorphism of interleukin-1 family, interleukin 6, and polymorphic GT repeat of the CRP gene do affect the usual CRP concentrations when a person does not have any medical illnesses.
== Secretion efficiency determination == Signal peptides are extremely heterogeneous, many prokaryotic and eukaryotic ones are functionally interchangeable within or between species and all determine protein secretion efficiency.
=== Synthesis === The first reported manufacturing process for pregabalin was reported by Hoekstra and colleagues at Warner-Lambert in 1997, developed under the investigational name CI-1008. Initial preparations used an Evans chiral auxiliary to establish the (S)-stereocentre, but the selected manufacturing route employed racemic synthesis of 3-(aminomethyl)-5-methylhexanoic acid followed by diastereomeric salt formation with (S)-(+)-mandelic acid as the resolving agent. A more efficient enantioselective route was subsequently reported by Burk and colleagues, in which asymmetric hydrogenation of a salt of 3-cyano-5-methylhex-3-enoic acid using a rhodium/(R,R)-Me-DuPHOS catalyst gives the (S)-cyano intermediate in high enantiomeric excess (≥95% ee), followed by heterogeneous nickel-catalysed hydrogenation of the nitrile to afford pregabalin. A second-generation chemoenzymatic manufacturing process reported by Pfizer in 2008 uses a lipase-catalysed kinetic resolution of 2-carboxyethyl-3-cyano-5-methylhexanoic acid ethyl ester (CNDE) with Lipolase (a Thermomyces lanuginosus lipase supplied commercially by Novozymes), followed by thermal decarboxylation and nitrile reduction to give the final product. Following patent expiry, generic manufacturing routes have also been developed, including a process reported by Dr. Reddy's Laboratories in 2021 that combines continuous-flow nitroalkene synthesis with an asymmetric organocatalytic Michael addition as the stereodetermining step.
=== Subcutaneous implant === Testosterone can be administered in the form of a subcutaneous pellet implant. The bioavailability of testosterone when administered as a subcutaneous pellet implant is virtually 100%. Levels of testosterone vary considerably between individuals, but are fairly constant within individuals. The absorption half-life of subdermal testosterone implants is 2.5 months. The replacement interval is once every four to six months. A single 50 mg testosterone pellet implanted every 4 to 6 months has been found to result in testosterone levels of 70 to 90 ng/dL in women.
The effects of liposuction on obesity are less well determined. Some small studies show benefits while others show none. A treatment involving the placement of an intragastric balloon via gastroscopy has shown promise. One type of balloon led to a weight loss of 5.7 BMI units over 6 months or 14.7 kg (32 lb). Regaining lost weight is common after removal, however, and 4.2% of people were intolerant of the device. An implantable nerve simulator which improves the feeling of fullness was approved by the FDA in 2015. In 2016 the FDA approved an aspiration therapy device that siphons food from the stomach to the outside and decreases caloric intake. As of 2015 one trial shows promising results.
Sources: en.wikipedia.org
== Awards and honors == He was awarded the Louisa Gross Horwitz Prize from Columbia University in 1991, the Louis-Jeantet Prize for Medicine in 1993, the Otto Warburg Medal in 1999 and half of the Nobel Prize in Chemistry in 2002 for "his development of nuclear magnetic resonance spectroscopy for determining the three-dimensional structure of biological macromolecules in solution". He received the Bijvoet Medal of the Bijvoet Center for Biomolecular Research of Utrecht University in 2008. He was elected a Foreign Member of the Royal Society (ForMemRS) in 2010. In 2017 he was awarded the Endel Lippmaa Memorial Medal by the Estonian Academy of Sciences. He was also awarded the 2018 Fray International Sustainability Award at SIPS 2018 by FLOGEN Star Outreach.
Simon and Schuster. ISBN 978-1-4262-2005-0. Archived from the original on January 8, 2023. Retrieved January 8, 2023. Gainor, Chris (2001). Arrows to the Moon: Avro's Engineers and the Space Race. Burlington, Ontario: Apogee Books. ISBN 1-896522-83-1. Archived from the original on July 23, 2008. Retrieved August 2, 2019. Gatland, Kenneth (1976). Manned Spacecraft, Second Revision. New York: Macmillan Publishing Co., Inc. ISBN 0-02-542820-9. Hall, Rex; Shayler, David J. (2001). The Rocket Men: Vostok & Voskhod, The First Soviet Manned Spaceflights. New York: Springer–Praxis Books. ISBN 1-85233-391-X. Hall, Rex; Shayler, David J. (2003). Soyuz: A Universal Spacecraft. New York: Springer–Praxis Books. ISBN 1-85233-657-9. Hardesty, Von; Eisman, Gene (2007). Epic Rivalry: The Inside Story of the Soviet and American Space Race. Foreword by Sergei Khrushchev. Washington: National Geographic Society. ISBN 978-1-4262-0119-6. Harford, James J. (1997). Korolev: How One Man Masterminded the Soviet Drive to Beat America to the Moon (1 ed.). New York: John Wiley & Sons. ISBN 0-471-14853-9. Hepplewhite, T.A. (1999). The Space Shuttle Decision: NASA's Search for a Reusable Space Vehicle. Washington, DC: NASA. Jones, Eric M. (January 1, 2010). "Apollo 11 Lunar Surface Journal". Apollo Lunar Surface Journal. Internet. Archived from the original on January 16, 2012. Retrieved August 15, 2010. Kraft, Christopher C. (2001). Flight: My Life in Mission Control. New York: Dutton. ISBN 0-525-94571-7. Murray, Charles; Cox, Catherine Bly (1990). Apollo: The Race to the Moon.
Tetrameric, dimeric, and, more recently, monomeric αM protease inhibitors have been identified. α2-Macroglobulin is able to inactivate an enormous variety of proteinases (including serine-, cysteine-, aspartic- and metalloproteinases). It functions as an inhibitor of fibrinolysis by inhibiting plasmin and kallikrein. It functions as an inhibitor of coagulation by inhibiting thrombin. α2-Macroglobulin has in its structure a 35 amino acid "bait" region. Proteinases binding and cleaving the bait region become bound to α2M. The proteinase–α2M complex is recognised by macrophage receptors and cleared from the system.
== Function == The GLP2 receptor (GLP2R) is a G protein-coupled receptor superfamily member closely related to the glucagon receptor (GLP1 receptor). Glucagon-like peptide-2 (GLP2) is a 33-amino acid proglucagon-derived peptide produced by intestinal enteroendocrine cells. Like glucagon-like peptide-1 (GLP1) and glucagon itself, it is derived from the proglucagon peptide encoded by the GCG gene. GLP2 stimulates intestinal growth and upregulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. Moreover, GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut and closely related to the glucagon receptor (GCGR) and the receptor for GLP1 (GLP1R).
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。